Postherpetic Neuralgia
📧 Sign up to get email alerts when something new happens for Postherpetic Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-01-13FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for gabapentin from Actavis Pharma, Inc., updating the approval status for this generic product.
-
FDA approval · 2015-12-23FDA Approved: GABAPENTIN — Original Application (Ascend Laboratories, LLC)
FDA approved the gabapentin original application for Ascend Laboratories, LLC, enabling a generic version of gabapentin.
-
CLINICAL_TRIALS trial_result · 2015-11-23Clinical Trial Update: A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005) [Phase 2]
This trial update indicates that the Phase 2 study of MK0686 for postherpetic neuralgia has been terminated.
-
CLINICAL_TRIALS trial_result · 2015-11-05Clinical Trial Update: Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating the efficacy and safety of lidocaine infusion for neuropathic pain m…
-
CLINICAL_TRIALS trial_result · 2015-09-28Clinical Trial Update: Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain
A completed GlaxoSmithKline-sponsored clinical trial in Spain aimed at estimating the burden of herpes zoster and postherpetic neuralgia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-09-17FDA Approved: GABAPENTIN — Supplemental Application (Advagen Pharma Ltd)
FDA approved a supplemental application for gabapentin filed by Advagen Pharma Ltd. The approval updates the approved generic product as par…
-
FDA approval · 2015-09-17FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
The FDA approved a supplemental application for Gabapentin from Granules Pharmaceuticals Inc, authorizing a generic gabapentin product to be…
-
FDA approval · 2015-09-10FDA Approved: GABAPENTIN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for gabapentin filed by Sun Pharmaceutical Industries, Inc. The approval reflects a supplemental cha…
-
CLINICAL_TRIALS withdrawal · 2015-08-26Clinical Trial Update: Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN [Phase 2]
A Phase 2 dose-ranging trial investigating EMA401 for postherpetic neuralgia was withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia [Phase 2]
A Phase 2 trial of ADL5747 for postherpetic neuralgia was terminated, with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-05-22Clinical Trial Update: Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN) [Phase 4]
Phase 4 clinical trial update for pregabalin in postherpetic neuralgia (PHN) with completed status and results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004) [Phase 2]
This Phase 2 trial update reports on the safety and preliminary efficacy of MK0759 for postherpetic neuralgia, with the study status listed …
-
FDA approval · 2015-04-21FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc.
-
FDA approval · 2015-04-17FDA Approved: GABAPENTIN — Supplemental Application (Advagen Pharma Ltd)
FDA approved a supplemental application for gabapentin submitted by Advagen Pharma Ltd under the existing ANDA. This action updates the regu…
-
FDA approval · 2015-04-17FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved a supplemental application for gabapentin granules from Granules Pharmaceuticals Inc.
-
FDA approval · 2015-03-31FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin filed by Quallent Pharmaceuticals Health LLC under ANDA200651.
-
FDA approval · 2015-03-16FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Gabapentin from Actavis Pharma, Inc., resulting in approval of a generic gabapentin product.
-
FDA approval · 2015-03-05FDA Approved: GABAPENTIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Gabapentin from Aurobindo Pharma Limited, enabling the generic product's continued marketing und…
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Validation Study of Neuropathic Pain
A completed validation study of neuropathic pain conditions, including spinal cord injury-related neuropathic pain, diabetic peripheral neur…
-
FDA approval · 2015-01-07FDA Approved: LIDOCAINE — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for lidocaine patch 5% (Lidocaine Patch) from Endo USA, Inc., resulting in updated labeling for …
-
FDA approval · 2014-11-08FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for gabapentin (generic anticonvulsant) under the approved ANDA.
-
FDA approval · 2014-11-08FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for gabapentin submitted by Ascend Laboratories, LLC (ANDA 090858).
-
FDA approval · 2014-10-23FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin filed by Quallent Pharmaceuticals Health LLC under ANDA200651, enabling marketing of …
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN) [Phase 2]
An open-label, follow-on Phase 2 trial evaluating the long-term safety and efficacy of oral SPM 927 in subjects with postherpetic neuralgia,…
-
FDA approval · 2014-08-18FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) by Parke-Davis (Pfizer), resulting in updated labeling.